Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2011-08-23
2011-08-23
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C514S058000
Reexamination Certificate
active
08003125
ABSTRACT:
A cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug. The polymer is selected from poly(ethylene glycol), derivatives thereon or a copolymer with a poly(ethylene glycol) segment. The copolymer with a poly(ethylene glycol) segment may include a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins. The composition may be injected subcutaneously, intramuscularly, intradermally, or intracranially.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4449938 (1984-05-01), Pollak
patent: 4609546 (1986-09-01), Hiratani
patent: 5143724 (1992-09-01), Leshchiner et al.
patent: 5256652 (1993-10-01), El-Rashidy
patent: 5298410 (1994-03-01), Phillips et al.
patent: 5324718 (1994-06-01), Loftsson
patent: 5324775 (1994-06-01), Rhee et al.
patent: 5413797 (1995-05-01), Khan et al.
patent: 5472954 (1995-12-01), Loftsson
patent: 5482719 (1996-01-01), Guillet et al.
patent: 5855900 (1999-01-01), Nobuhiko
patent: 5922340 (1999-07-01), Berde et al.
patent: 5939453 (1999-08-01), Heller et al.
patent: 5942241 (1999-08-01), Chasin et al.
patent: 5968543 (1999-10-01), Heller et al.
patent: 6083534 (2000-07-01), Wallach et al.
patent: 6096303 (2000-08-01), Fick
patent: 6331311 (2001-12-01), Brodbeck et al.
patent: 0 154 316 (1985-09-01), None
patent: 0 510 356 (1992-10-01), None
patent: 94/01483 (1994-01-01), None
patent: 94/14421 (1994-07-01), None
patent: 95/05164 (1995-02-01), None
patent: 95/11924 (1995-05-01), None
patent: 98/55148 (1998-12-01), None
patent: 99/09149 (1999-02-01), None
patent: 00/33885 (2000-06-01), None
patent: 00/40962 (2000-07-01), None
patent: 00/50007 (2000-08-01), None
patent: 00/64977 (2000-11-01), None
Li et al. Polymer Journal, 1994, vol. 2, pp. 1019-1026.
Jeong et al. Nature, 1997, vol. 388, pp. 860-862.
Amiel, C. et al., “New Associating Polymer Systems Involving Water Soluble Beta-Cyclodextrin Polymers,” J. Inclusion Phen. Mol. Recog., 1996, 25, 61-67.
Li, J et al., Sol-Gel Transition during Inclusion Complex Formation between alpha Cyclodextrin and High Molecular Weight Poly(ethylene glycol)s in Aqueous Solution. Polymer Journal. vol. 26 No. 9 pp. 1019-1026 (1994).
Jeong et al., “biodegradable block copolymers as injectable drug-delivery system,” Nature I, vol. 388, p. 860-862. Aug. 1997.
Li, Jun, et al., “Sol-Gel Transition during Inclusion Complex Formation between α-Cyclodextrin and High Molecular Weight Poly(ethylene glycol)s in Aqueous Solution,”Polymer Journal, vol. 26, No. 9, pp. 1019-1026 (1994).
Chen, Guohua, and Hoffman, Allan S., “Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH,”Nature, vol. 373, pp. 49-52 (Jan. 5, 1995).
Jeoung, Byeongmoon, et al., “Biodegradable block copolymers as injectable drug-delivery systems,”Nature, vol. 388, 860-862 (Aug. 28, 1997).
Kwon, Ick Chan, et al., “Electrically erodible polymer gel for controlled release of drugs,”Nature, vol. 354, pp. 291-293 (Nov. 28, 1991).
Leong, K.W., et al., “DNA-polycation nanospheres as non-viral gene delivery vehicles,”Journal of Controlled Release, vol. 53, pp. 183-193 (1998).
BASF,Pluronic&Tetronic Surfactants, BASF Co., Mount Olive, New Jersey, 29 pages (1989).
(Abstract) March, K.L., et al., “Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth-muscle cells—modulation by poloxamer-407 and implications for cardiovascular gene-therapy,”Human Gene Therapy, vol. 6, No. 1, pp. 41-53 (Jan. 1995).
Loftsson, T., “Increasing the Cyclodextrin Complexation of Drugs and Drug Biovailability through Addition of Water-Soluble Polymers,”Pharmazie, vol. 53, pp. 733-740 (1998).
Ooya, T. et al., “Synthesis and Characterization of Biodegradable Polyrotaxane as a Novel Supramolecular-structured Drug Carrier,”J. Biomater. Sci. Polymer Edn., vol. 8, No. 6, pp. 437-455 (1997).
Ooya, T., et al., “Synthesis of Biodegradable Polymeric Supramolecular Assembly for Drug Delivery,”Macromol. Rapid Commun., vol. 16, pp. 259-263 (1995).
Jeong, B. et al., “Drug Release from Biodegradable Injectable Thermosensitive Hydrogel of PEG-PLGA-PEG Triblock Copolymers,”Journal of Controlled Release, vol. 63, pp. 155-163 (2000).
Ooya, T. et al., “Regulation of Intracellular Metabolism by Biodegradable Polyrotaxanes,”J. Biomater. Sci. Polymer Edn., vol. 9, No. 4, pp. 313-326 (1998).
Ooya, T. et al., “Synthesis of Theophylline-polyrotaxane Conjugates and Their Drug Release Via Supramolecular Dissociation,”Journal of Controlled Release, vol. 58, pp. 251-269 (1999).
Ooya, T. et al., “Polyrotaxanes: Synthesis, Structure, and Potential in Drug Delivery,”Critical Reviews in Therapeutic Drug Carrier Systems, vol. 16, No. 3, pp. 289-330 (1999).
Watanabe, J. et al., “Effect of Acetylation of Biodegradable Polyrotaxanes on its Supramolecular Dissociation Via Terminal Ester Hydrolysis,”J. Biomater. Sci. Polymer Edn., vol. 10, No. 12, pp. 1275-1288 (1999).
Yui, N. et al., “Effect of Biodegradable Polyrotaxanes on Platelet Activation,”Bioconjugate Chem., vol. 9, No. 1, pp. 118-125 (1998).
Injectable drug-delivery systems based on supramolecular hydrogels formed by poly(ethylene oxide)s and α-cyclodextrin: Jun Li, Xiping Ni, Kam W. Leong: 2003 Wiley Periodicals, Inc. pp. 196-202.
Ceccato, M., et al., “α-CylcoDextrin/Polyethylene Gycol Polyrotaxane: A Study of the Threading Process,”Langmuir, vol. 13, No. 9, pp. 2436-2439 (1997).
Kamimura, W., et al., “Interaction of Supermolecular Assembly with Hairless Rat Stratum Corneum,”Journal of Controlled Release, 44, pp. 295-299 (1997).
Ooya, T., et al., “Novel Design of Biodegradable Supramolecular Assembly for Drug Delivery,”Fifth World Biomaterials Congress, Toronto, Canada, p. 470 (May 29-Jun. 2, 1996).
Watanabe, J., et al., “Preperation and Characterization of Poly(Ethylene Glycol) Hydrogels Cross-Linked by Hydrolyzable Polyrotaxane,”J. Biomater. Sci. Polymer Edn, vol. 11, No. 12, pp. 1333-1345 (2000).
Yui, N., et al., “Supramolecular-Structured Polymers for Drug Delivery,”Japan Advanced Institute of Science and Technology, School of Materials Science, pp. 308-309 (1999).
Leong Kam
Li Jun
Yu Hanry
Agency for Science Technology and Research
Kilpatrick Townsend & Stockton LLP
Peselev Elli
LandOfFree
Injectable drug delivery systems with cyclodextrin-polymer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injectable drug delivery systems with cyclodextrin-polymer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injectable drug delivery systems with cyclodextrin-polymer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708971